Key facts
- Trilobio’s last known valuation is $25.0M (May 2025).
- It has raised $11.0M; the latest was Seed Round ($8.0M) in May 2025.
- Notable investors include Alumni Ventures, Mana Ventures, Climate Capital, Gaingels, Hustle Fund — 28 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Trilobio
- ·The full record, as it builds
Funding rounds
No funding rounds for Trilobio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Trilobio
Developer of an end-to-end automated synthetic biology platform designed to provide medical services. The company's platform specializes in assembling deoxyribonucleic acid as a service with end-to-end automation and the parts can be freely shared and used, it works on robotics, software and genetic engineering, enabling the healthcare industry to use them for medical and other commercial use.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Employees
- 7
- Website
- trilo.bio/
- Ownership
- Privately Held (backing)
Trilobio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trilobio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trilobio in its N-PORT filings yet. We sweep new filings monthly.